LabCorp Offering Veridex's CTC Test for Clinical Trials Research in China | GenomeWeb

NEW YORK (GenomeWeb News) – Veridex announced this week a deal with Laboratory Corporation of America to make its CellSearch circulating tumor cell test available in China.

LabCorp's Beijing central laboratory is now the first clinical reference laboratory in the country to offer CTC testing and will offer the test to researchers conducting clinical trials.

The agreement follows regulatory approval in China last month for the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: transcriptomic analysis of the Venus flytrap, SMASH approach for CNV analysis, and more.

A Caltech professor wins the Millennium Technology Prize that lauds technological advances that improve human life.

San Diego's biotech scene has a dearth of executives who are women, Stat News reports.

Some 90 percent of respondents to a Nature survey say there is a research reproducibility crisis.